MXCT
MaxCyte, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.28
+1.59%Aug 19, 2026, 12:05 UTC
MaxCyte, Inc. launched the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays, available through its SeQure™ service, to improve off-target assessment for genome editing therapies.
Source:Aug 12, 2026, 20:05 UTC
MaxCyte reported total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue.
Aug 12, 2026, 20:05 UTC
MaxCyte repurchased approximately $5.5 million of its common stock under its $10 million share repurchase program authorized by the Board.
Source:Jul 21, 2026, 12:05 UTC
MaxCyte entered into a multi-platform technology license partnership with Genentech to support cell therapy development.
Source:Jun 16, 2026, 00:00 UTC
MaxCyte, Inc. regained compliance with NASDAQ's minimum bid price requirement under Rule 5450(a)(1).